Literature DB >> 12898082

Rofecoxib interaction with oral anticoagulant acenocoumarol.

François Girardin, Michèle Siegenthaler, Philippe De Moerloose, Jules Desmeules.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898082     DOI: 10.1007/s00228-003-0628-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.

Authors:  C Verstuyft; S Morin; A Robert; M A Loriot; P Beaune; P Jaillon; L Becquemont
Journal:  Pharmacogenetics       Date:  2001-11

2.  The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

Authors:  J I Schwartz; K J Bugianesi; D L Ebel; M De Smet; R Haesen; P J Larson; A Ko; R Verbesselt; T L Hunt; R Lins; S Lens; A G Porras; J Dieck; B Keymeulen; B J Gertz
Journal:  Clin Pharmacol Ther       Date:  2000-12       Impact factor: 6.875

3.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

4.  Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.

Authors:  H H Thijssen; J P Flinois; P H Beaune
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

5.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.